ARQT Arcutis Biotherapeutics, Inc.
USHealthcareAs of 2026-07-10 15:45
Why ARQT matters now
Arcutis Biotherapeutics, Inc. (ARQT) is a US stock in Healthcare. The latest InvestLog snapshot shows $27.39 with -4.83% on the session and $3.43B in market capitalization; recent performance reads 1-month +34.41% and YTD -9.75%.
The latest financial table shown here is Q1 2026, with revenue of $105.4M, net income of $-11.3M, and EPS of $-0.09. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield 0.8%.
The latest indexable market news headline is "Biotech Stock Arcutis Climbs Into Buy Zone As FDA Mulls Expanded Use For Key Skin Treatment" from Investors Business Daily.
Additional event context on this page matters because analyst consensus is Buy with a median target of $34.00; recent insider activity includes Welgus Howard G. filing S-Sale; recent congressional disclosure data includes Gilbert Cisneros Purchase. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
17.88
P/S
7.89
EV/EBITDA
216.72
DCF Value
$-173.74
FCF Yield
0.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
90.9%
Operating Margin
0.8%
Net Margin
-0.6%
ROE
-1.4%
ROA
-0.5%
ROIC
1.1%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $105.4M | $-11.3M | $-0.09 |
| Q4 2025 | $129.5M | $17.4M | $0.13 |
| FY 2025 | $376.1M | $-16.1M | $-0.13 |
| Q3 2025 | $99.2M | $7.4M | $0.06 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$34.00
Target (Median)
$34.00
Target Range
$34.00 - $34.00
Trading Activity
Insider Trades
Congress Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.52
Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for a range of skin-related diseases. The company's flagship investigational compound, ARQ-151, a roflumilast cream administered topically, has successfully concluded late-stage clinical development for treating both plaque psoriasis and atopic dermatitis. Beyond its lead asset, Arcutis's pipeline includes several other promising compounds. Among these is ARQ-154, a roflumilast foam applied topically, aimed at seborrheic dermatitis and scalp psoriasis. Furthermore, ARQ-252, a topical selective Janus kinase type 1 (JAK1) inhibitor, is under investigation for hand eczema and vitiligo. ARQ-255, a variation of ARQ-252 designed for deeper dermal absorption, is being explored for alopecia areata. Established in 2016, the company was initially named Arcutis, Inc. before changing to Arcutis Biotherapeutics, Inc. in October 2019. Its corporate headquarters are situated in Westlake Village, California.